FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Breast Cancer

On May 4, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and who have developed disease recurrence during or within six months of completing therapy.

Read the FDA announcement.

Read AstraZeneca and Daiichi Sankyo's announcement.

Posted 5/5/2022